Skip to content

Insmed INSM Price / book

Price / book at other companies

United Therapeutics logo
United TherapeuticsUTHR
4.4×+2.4×
Incyte logo
IncyteINCY
3.3×+0.1×
Amgen logo
AmgenAMGN
20.6×-6.3×
ALN
Alnylam PharmaceuticalsALNY
40.8×-41.2×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
3.9×-0.5×
Johnson & Johnson logo
Johnson & JohnsonJNJ
7.3×+2.1×

Other financials

Income statement

See full
Revenue$306.0M+230%
Gross profit$258.5M+261%
Operating income-$153.3M+38.2%
Net income-$163.6M+36.3%
EPS (diluted)-$0.76+46.5%

Balance sheet

See full
Cash & equivalents$582.2M+44.4%
Total debt$580.3M-49.2%
Total equity$704.9M+611%
Total assets$2.1B+15.2%

Cash flow

See full
Operating cash flow-$222.7M+15.0%
CapEx$3.5M-65.4%
Free cash flow-$226.2M+16.9%

Valuation

See full
Market cap$20.76B+155%
Enterprise value$20.76B+142%
P/S25.3×+4.0×

Profitability

See full
Gross margin81.8%+5.3pp
Operating margin-140.6%-43.9pp
Net margin-144.4%-45.3pp

Returns & leverage

See full
Return on equity-294.5%
Debt / equity0.8×-10.7×
Current ratio4.5×-1.4×

Where this comes from

Calculated from Insmed’s reported figures.

Based on the most recent quarter.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insmed's price / book?
Insmed (INSM) reported price / book of 50× in Q1 2026.
How has Insmed's price / book changed year-over-year?
Insmed's price / book decreased by 64.1% year-over-year, from 139.3× to 50×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.